Favorable Media Coverage Somewhat Unlikely to Impact Bioanalytical Systems (BASI) Stock Price

Media coverage about Bioanalytical Systems (NASDAQ:BASI) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.5781300805918 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Bioanalytical Systems (NASDAQ BASI) opened at $2.64 on Tuesday. Bioanalytical Systems has a 1 year low of $0.65 and a 1 year high of $2.95. The firm has a market cap of $21.76, a price-to-earnings ratio of -15.53 and a beta of 1.36. The company has a quick ratio of 0.51, a current ratio of 0.64 and a debt-to-equity ratio of 0.60.

TRADEMARK VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Impact Bioanalytical Systems (BASI) Stock Price” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/12/26/favorable-media-coverage-somewhat-unlikely-to-impact-bioanalytical-systems-basi-stock-price.html.

Bioanalytical Systems Company Profile

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit